Implantable Infusion Pumps Market Report 2026

Implantable Infusion Pumps Market Overview

• Implantable Infusion Pumps market size has reached to $20.32 billion in 2025 • Expected to grow to $28.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Rising Aging Population Driving Market Growth Due To Increased Demand For Chronic Disease Management Solutions • Market Trend: Product Innovations In The Implantable Infusion Pumps Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Implantable Infusion Pumps Market?

Implantable infusion pumps refer to medical devices surgically placed under the skin that deliver precise, controlled doses of medication directly into the bloodstream, spinal fluid, or specific body sites over an extended period. They are used for managing chronic conditions such as cancer pain, spasticity, and diabetes, improving treatment effectiveness and reducing systemic side effects. The implantable infusion pumps market is segmented by type into patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. The insulin pump is a small device that is put beneath the skin during the operation to deliver insulin in diabetic patients. The various applications of implantable infusion pumps are oncology, pediatrics/neonatology, gastroenterology, hematology, diabetes, and others that are used by hospitals, ambulatory surgical centers, and specialty clinics.

What Is The Implantable Infusion Pumps Market Growth Forecast?

The implantable infusion pumps market size is expected to see strong growth in the next few years. It will grow to $28.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of smart infusion technologies, rising demand for remote patient monitoring, expansion of personalized dosing regimens, growing investments in digital therapeutics, increasing use of implantable pumps in homecare settings. Major trends in the forecast period include increasing adoption of programmable infusion pumps, rising demand for long-term pain management solutions, growing use of smart and connected pumps, expansion of implantable insulin delivery systems, enhanced focus on dose accuracy.

Global Implantable Infusion Pumps Market Segmentation

1) By Type: Patient-Controlled Analgesia (PCA) Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Syringe Pumps, Other Types 2) By Applications: Oncology, Pediatrics Or Neonatology, Gastroenterology, Hematology, Diabetes, Other Applications 3) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics Subsegments: 1) By Patient-Controlled Analgesia (PCA) Pumps: Morphine PCA Pumps, Fentanyl PCA Pumps, Other Opioid PCA Pumps 2) By Enteral Pumps: Tube Feeding Pumps, Syringe-based Enteral Pumps, Continuous Or Intermittent Feeding Pumps 3) By Insulin Pumps: Insulin Delivery Pumps, Insulin Patch Pumps, Smart Insulin Pumps 4) By Elastomeric Pumps: Disposable Elastomeric Pumps, Reusable Elastomeric Pumps 5) By Syringe Pumps: Small Volume Syringe Pumps, Large Volume Syringe Pumps 6) By Other Types: Chemotherapy Infusion Pumps, Antibiotic Infusion Pumps, Pain Management Pumps

What Is The Driver Of The Implantable Infusion Pumps Market?

The increase in the aging population is expected to boost the growth of the implantable infusion pumps market going forward. The aging population refers to the percentage of people 65 and older to those between the ages of 18 and 64 who are employed. The rising aging population is due to increased life expectancy resulting from advances in healthcare and living standards, leading to more people living longer. Implantable infusion pumps are frequently used in the management of chronic conditions, which means that an aging population leads to a greater pool of potential patients who can benefit from these devices. For instance, in February 2025, according to Eurostat, a Luxembourg statistical office of the European Union, the European Union had an estimated population of approximately 449 million people in 2024, with more than one-fifth or 21.6% aged 65 years and over and a median age of 44.7 years, with the old-age dependency ratio in the EU rose by half a percentage point (0.5 pp) between 2023 and 2024, climbing from 33.4% to 33.9%. Therefore, the increase in the aging population is driving the growth of the implantable infusion pumps industry.

Key Players In The Global Implantable Infusion Pumps Market

Major companies operating in the implantable infusion pumps market are Medtronic plc, Boston Scientific Corporation, Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical a Smiths Group company, Terumo Corporation, Johnson & Johnson, Greatbatch Medical, Primetech Corporation, Flowonix Medical Inc., F. Hoffmann-La Roche Ltd, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Micrel Medical, Insulet Corporation, ICU Medical Inc., Becton Dickinson and Company (BD), Roche Diagnostics International AG, Abbott Laboratories, Hospira, Teleflex Incorporated, C. R. Bard Inc., AngioDynamics Inc., Merit Medical Systems Inc., NIPRO Medical Corporation, IRadimed Corporation, Zyno Medical, Tricumed Medizintechnik GmbH, Q Core Medical Ltd., Ivenix Inc., Tandem Diabetes Care Inc.

Global Implantable Infusion Pumps Market Trends and Insights

Major companies operating in the implantable infusion pumps market are developing new products such as insulin pumps to meet larger customer bases, more sales, and increase revenue. Insulin pumps are medical devices designed to assist individuals with diabetes in managing their blood sugar levels. For instance, in April 2023, Medtronic, an Ireland-based medical device company, announced the FDA approval for the MiniMed 780G System with meal detection technology. One distinctive aspect of this product is its ability to set the lowest glucose target (as low as 100 mg/dL) among all automated insulin pumps available in the market, thereby closely resembling the average glucose levels of individuals without diabetes. This setting enables the pump to operate on a treat-to-target basis, automatically making basal insulin adjustments and autocorrections to reach a specific target. Additionally, it stands out as the only pump equipped with an infusion set that can be comfortably worn for a prolonged period of up to 7 days. This extended wear time is made possible through the use of advanced materials that minimize insulin preservative loss and maintain consistent insulin flow and stability, ultimately reducing the chances of infusion set occlusion.

What Are Latest Mergers And Acquisitions In The Implantable Infusion Pumps Market?

In May 2025, Boston Scientific, a US-basedmedical device company, acquired Intera Oncology, Inc. for approximately $172 million. With this acquisition, Boston Scientific gains Intera Oncology's specialized Intera 3000 Hepatic Artery Infusion Pump and associated floxuridine drug, and its integration enhances Boston Scientific's interventional oncology offerings by adding a proven, targeted Hepatic Artery Infusion (HAI) therapy system for treating liver tumors. Intera Oncology, Inc. is a US-based provider of implantable infusion pumps and chemotherapy drug delivery systems, with a strong track record in hepatic artery infusion therapy.

Regional Outlook

North America was the largest region in the implantable infusion pumps market in 2025. Asia-Pacific was the second-largest region in the implantable infusion pumps market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Implantable Infusion Pumps Market?

The implantable infusion pumps market consists of sales of instruments such as patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.